LYON, France--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) today reported summary data from clinical studies of its lead product, ADVEXIN®. These data confirm and extend previous biomarker data correlating the abnormal p53 biomarker with increased tumor responses following ADVEXIN treatment and support its use as a biomarker to predict ADVEXIN efficacy. Additionally, data are being presented demonstrating clinical benefit of ADVEXIN in a patient with a rare inherited form of cancer known as Li-Fraumeni Syndrome (LFS), a genetic disorder characterized by inherited mutations in the p53 tumor suppressor gene. These data have been the subject of previous presentations at scientific and medical conferences.
